When taken together, these results demonstrate that lncRNA IGF2AS, antiPeg11, MEG3, and Zeb2NAT appear to be independent prognostic factors in BRAF-mutated advanced melanoma patients treated with vemurafenib. This evidence concerns the gene ZEB2-AS1 and melanoma.